Analysis of the phase 3 CheckMate-214 study has shown that the ipilimumab + nivolumab combination resulted in a significantly longer treatment-free survival period for patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) than patients who were treated with the standard of care, sunitinib. Data from the CheckMate-214 study were presented at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich over the weekend.
When the analysis was carried out, about 75% of the patients on the combination treatment and 85% in the sunitinib group had stopped treatment. Of the patients who stopped treatment, 19% in the combination group, versus 4% in the sunitinib group remained treatment-free after 18 months.
Treatment-free survival was significantly longer with the ipilimumab + nivolumab combination than sunitinib, regardless of best overall response. After a follow-up of 30 months, 36% of patients in the combination group were still alive and not requiring subsequent therapy versus 16% who received sunitinib.
“This latest analysis demonstrating sustained clinical benefit over time builds on the existing body of evidence from CheckMate-214 regarding superior overall survival and durable response, regardless of PD-L1 expression, and reinforces our ongoing commitment to improving outcomes for adults living with the most common type of kidney cancer,” said Arvin Yang, development lead of melanoma and genitourinary cancers at Bristol-Myers Squibb in a statement.